Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Unknown

In vitro and mouse studies identified fucosylation inhibitors that could help treat various diseases including cancers. A screen of about 200 synthetic fucose-related compounds identified molecules that inhibited fucosylation of antibodies. In vitro,
the lead fucosylation inhibitor was used to generate fucose-deficient antibodies, which showed greater binding affinity and cytotoxicity than parent antibodies. In mice, oral treatment with 2-fluorofucose increased survival in a lymphoma model compared with no treatment and delayed tumor growth in a colorectal cancer model. Next steps could include testing the fucosylation inhibitors in other indications.

SciBX 6(12); doi:10.1038/scibx.2013.284
Published online March 28, 2013

Patent and licensing status unavailable

Okeley, N.M. et al. Proc. Natl. Acad. Sci. USA; published online March 14, 2013;
doi:10.1073/pnas.1222263110
Contact: Peter D. Senter, Seattle Genetics Inc., Bothell, Wash.
e-mail:

psenter@seagen.com